Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

GSK hails 'milestone' drug trial results in China

Fri 10 Jul 2026 11:54

(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip confirmed on Friday. The UK firm said the Artemis-008 phase III trial evaluating risvutatug rezetecan (ris-rez) in patients with advanced or relapsed small-cell lung cancer (SCLC) had met its primary endpoint of overall survival. In particular, it demonstrated "statistically significant and clinically meaningful improvements" in overall survival compared with the standard of care, chemotherapy drug topotecan.

SCLC is a difficult to treat, aggressive cancer, with limited treatment options and a poor prognosis.

The data will now be used by Hansoh Pharmaceutical Group, GSK's licensor, for regulatory submission in China for the investigational B7-H3-targeted antibody-drug conjugate (ADC). GSK holds exclusive global rights to develop ris-rev outside mainland China, Hong Kong, Macau and Taiwan.

Hesham Abdullah, global head of oncology research and development at GSK, said: "These results are an important milestone as the first positive phase III survival data for B7-H3-targeted ADC in any tumour type.

"Together with other data generated to date, they further support the potential of B7-H3 as a promising target across lung cancer and other solid tumours, and reinforce our continued development of ris-rez to improve standard of care in areas of high unmet need."

As at 1300 BST, shares in GSK were up 1% at 1,973p.

See latest RNS on Investegate

Share this article

Related Sharecast Articles

Tue 18 Aug 2026 09:49
Bernstein upgrades Whitbread to 'market perform', says 5-year plan is 'realistic'
(Sharecast News) - Bernstein upgraded Whitbread on Tuesday to 'market perform' from 'underperform' and lifted the price target to 2,400p from 2,100p as it said the company's new five-year plan was "realistic" and it's time to adopt a "more constructive stance".
Tue 18 Aug 2026 08:47
RHI Magnesita taps Gustavo Franco for CEO
(Sharecast News) - Refractory products and services group RHI Magnesita said on Tuesday that chief executive Stefan Borgas will step down at the end of October and retire from executive roles, with Gustavo Franco appointed to succeed him from 1 November.
Tue 18 Aug 2026 08:44
BHP profits jump as copper becomes main driver for first time
(Sharecast News) - Australian mining giant BHP posted a sharp jump in annual earnings with copper became its main profit earner, overtaking iron ore for the first time.
Tue 18 Aug 2026 08:40
HgCapital Trust to invest around £20m in Nourish
(Sharecast News) - HgCapital Trust said on Tuesday that it was investing around £20m in Nourish, a provider of software for the UK social and community care sector.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026